INSIGHTS

The Shift Toward US Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix


white paper.svg WHITE PAPER

General


The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) reports 72% of facilities manufacturing APIs for American drugs are overseas, with 13% in China.

Download our white paper where we discuss effective strategies to secure and de-risk pharmaceutical supply chains and reveal how AMRI assures the continual production of urgently needed drugs.





 
Block 1
editable text
Block 2 Top
editable text
Block 2 Bottom
editable text
grows to fill column
Block 3 Top
editable text
Block 3 Bottom
editable text
grows to fill column
Block 4
editable text